Literature DB >> 20102362

Optimal design of pharmacokinetic studies.

Leon Aarons1, Kayode Ogungbenro.   

Abstract

Experimental design is fundamental to successful scientific investigation. Poorly designed experiments lead to the loss of information, which is costly and potentially unethical. Experiments can be designed in an optimal fashion to maximize the amount of information they provide. Optimal design theory uses prior information about the model and parameter estimates to optimize a function of the Fisher information matrix to obtain the best combination of the design factors. In the case of population pharmacokinetic experiments, this involves the selection and a careful balance of a number of design factors, including the number and location of measurement times and the number of subjects to include in the study. It is expected that as the awareness about the benefits of this approach increases, more people will embrace it and ultimately will lead to more efficient population pharmacokinetic experiments and can also help to reduce both cost and time during drug development. This MiniReview provides an introduction to optimal design using examples taken from different pharmacokinetic experiments.

Entities:  

Mesh:

Year:  2010        PMID: 20102362     DOI: 10.1111/j.1742-7843.2009.00533.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  15 in total

1.  Population pharmacokinetics of lamotrigine in Indian epileptic patients.

Authors:  Surulivelrajan Mallaysamy; Martin G Johnson; Padma G M Rao; Thiyagu Rajakannan; Lokesh Bathala; Karthik Arumugam; Johan G C van Hasselt; Devarakonda Ramakrishna
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Animal Pharmacokinetic/Pharmacodynamic Studies (APPS) Reporting Guidelines.

Authors:  Jasbir Singh; Fawzy Elbarbry; Ke Lan; Tomasz Grabowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

3.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

4.  Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

Authors:  A Kontou; K Sarafidis; O Begou; H G Gika; A Tsiligiannis; K Ogungbenro; A Dokoumetzidis; E Agakidou; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.

Authors:  Weikun Huang; You Zheng; Huiping Huang; Yu Cheng; Maobai Liu; Nupur Chaphekar; Xuemei Wu
Journal:  Eur J Clin Pharmacol       Date:  2022-06-28       Impact factor: 3.064

6.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

7.  Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Authors:  Michael Neely; Michael Philippe; Teresa Rushing; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Ther Drug Monit       Date:  2016-06       Impact factor: 3.681

8.  Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.

Authors:  A Taneja; J Nyberg; E C M de Lange; M Danhof; O Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

Review 9.  Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 5.577

10.  Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression.

Authors:  Emma C Martin; Leon Aarons; James W T Yates
Journal:  Toxicol Sci       Date:  2015-12-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.